Kesar Vivek, Kesar Varun, Khaitova Viktoriya, Motamed David, Schiano Thomas
J Drugs Dermatol. 2014 Feb;13(2):199-200.
Telaprevir, a protease inhibitor, was recently approved for management of Chronic Hepatits C (CHC) due to HCV genotype 1. Various RCTs have demonstarted increased incidence of cutaneous adverse effects with use of Telaprevir. Herein, we report two cases of drug rash with eosinophilia and systemic symptoms (DRESS) secondary to Telaprevir use.
特拉匹韦是一种蛋白酶抑制剂，最近被批准用于治疗丙型肝炎病毒1型引起的慢性丙型肝炎（CHC）。多项随机对照试验表明，使用特拉匹韦会增加皮肤不良反应的发生率。在此，我们报告两例因使用特拉匹韦继发的药物性皮疹伴嗜酸性粒细胞增多和全身症状（DRESS）。
